BMO Capital Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has initiated coverage on Neurogene (NASDAQ:NGNE) with an Outperform rating and a price target of $65.
June 27, 2024 | 9:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has initiated coverage on Neurogene with an Outperform rating and a price target of $65, indicating strong confidence in the company's future performance.
The initiation of coverage with an Outperform rating and a high price target by a reputable analyst is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100